accountNasdaq: ALKS The fit seems perfect for Alkermes, which also has an extended-release platform. It receives royalties from Johnson & Johnson's (NYSE: JNJ The addition of royalties from drugs such as Johnson & Johnson's Invega Sustenna and Acorda...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to In Biotech, Two Platforms Are Better Than One
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account